Analysts have pointed out that Smegglutide tablets are the first oral peptide drug in China, which may mean that similar oral peptide drugs are more likely to be approved in the future. At present, there are also several pharmaceutical companies in China that are developing oral peptide GLP-1 drugs, including East China Pharmaceutical, Xianweida, and Wentai Pharmaceutical.

Late night thunderstorm

On the evening of January 25th, when the US stock market opened, Intel's stock price suddenly plummeted, with the largest intraday decline exceeding 12%. As of the close, the decline still reached 11.9%, marking the largest daily decline in nearly two years. The total market value evaporated by $24.9 billion (approximately RMB 180 billion) in a single day, and the latest total market value shrank to $184.55 billion (approximately RMB 1330 billion).

On the news front, Intel recently released its fourth quarter financial report for the fiscal year 2023 (as of December 2023), which showed that Intel achieved revenue of $15.4 billion in the fourth quarter of 2023, slightly exceeding market expectations ($15.2 billion), a year-on-year increase of 10%, ending seven consecutive quarters of revenue decline; The net profit was 2.669 billion US dollars, turning losses into profits year-on-year, exceeding market expectations (957 million US dollars).

But in the latest financial report, Intel released a major bearish news - performance guidance for the first quarter of 2024. The company expects its revenue to reach $12.2 billion to $13.2 billion in the first quarter, far below market expectations of $14.27 billion; It is expected that the adjusted earnings per share under Non GAAP in the first quarter will be $0.13, lower than the market expectation of $0.34; The expected gross profit margin for the first quarter is 40.7%, significantly lower than the market expectation of 42.5%.

The expected revenue and gross profit margin are both lower than expected, mainly due to intensified competition in some businesses, which may lead to a decline in the company's performance.

Intel CEO Pat Gelsinger stated that the weak outlook for the first quarter of 2024 is only "temporary" as "the momentum and excitement of new products and businesses remain strong", and it is expected that "revenue and earnings per share for each quarter will achieve continuous and comparable growth" in the 2024 fiscal year.

Intel's business mainly consists of client business, data center and AI, network and edge domain, Mobileye, and wafer foundry services. Among them, client business, data center, and AI business are the largest sources of revenue for the company, with a combined proportion of over 80%.

Among them, Intel's data center and AI businesses achieved revenue of 3.985 billion US dollars in the fourth quarter of 2023, a year-on-year decrease of 7.4%. Mainly due to the shrinking potential market for CPUs, and with the gradual entry of competitors, the company's competitive pressure is still increasing.

Intel CFO David Zinner warned during a conference call that the company expects a "double-digit" decline in its data center business in the first quarter of 2024 compared to the previous quarter.